Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on August 5, 2020, to announce its financial and operating results for the second quarter ended June 30, 2020. The key information is contained within the press release furnished as Exhibit 99.1 to the filing. Investors should review the press release for detailed financial performance, including revenue, earnings per share, and updates on key product sales and pipeline developments. This filing serves as the official notification of the company's performance during the second quarter, providing essential data for evaluating the company's current financial health and future prospects.
Key Highlights
- 1Regeneron announced its financial and operating results for the second quarter ended June 30, 2020.
- 2The results were disclosed via a press release furnished as Exhibit 99.1 to the 8-K filing.
- 3The filing indicates the event date for these results was August 4, 2020, and it was filed on August 5, 2020.
- 4Investors are directed to Exhibit 99.1 for comprehensive details on the company's Q2 2020 performance.
- 5The information provided is not considered 'filed' for Section 18 of the Securities Exchange Act of 1934 purposes, but is incorporated by reference for investors to review.
Frequently Asked Questions
The detailed financial and operating results for the second quarter ended June 30, 2020, are available in the press release furnished as Exhibit 99.1 to this 8-K Current Report filed on August 5, 2020.
This 8-K filing serves as the official notification of Regeneron's second quarter 2020 financial and operating performance. It directs investors to the press release for the specific results, enabling them to assess the company's performance and make informed investment decisions.
The filing specifies that the information included or incorporated from the press release (Exhibit 99.1) is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated into other SEC filings unless expressly stated. This is a standard disclosure for press releases furnished under Item 2.02.